Abstract
Objectives
Limited work, either retrospective or prospective, has been done to investigate whether or not there is a cause-specific mortality (CSM) or all-cause mortality (ACM) benefit to adding surgery following neoadjuvant treatment for Stage IIIB NSCLC.
Methods
We extracted patients with Stage IIIB NSCLC from the Survival, Epidemiology, and End Results Program (SEER) database treated from 2004 to 2012 with either radiation alone or radiation followed by surgery. Other variables extracted were age, sex, race, and tumor location. The impact of patient and treatment variables on CSM and ACM was explored using Cox multivariable regression analysis.
Results
A total of 14,065 patients were extracted from the SEER database. On multivariable analysis, even after adjustment for age, gender, race, and site, radiation followed by surgery was associated with a reduction in cause-specific mortality compared to radiation alone (adjusted HR 0.46; 95 % CI 0.41, 0.52; p < 0.0001). Median overall survival was 11 months in the radiotherapy alone arm versus 29 months in the radiotherapy plus surgery arm (p < 0.0001 by log-rank test). After adjustment for these same factors, radiation followed by surgery was also associated with a reduction in all-cause mortality compared with radiation alone (adjusted HR 0.47; 95 % CI 0.42, 0.52; p < 0.0001). Median cause-specific survival was 12 months in the radiotherapy alone arm versus 33 months in the radiotherapy plus surgery arm (p < 0.0001 by log-rank test).
Discussion
In the SEER database, there appears to be both a CSM and ACM benefit to adding surgery following radiation for Stage IIIB NSCLC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Albain KS, Swann RS, Rusch VW, Turrisi AT, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara DR, Fry WA, Darling G, Johnson DH, Green MR, Miller RC, Ley J, Sause WT, Cox JD (2009) Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 374(9687):379–386
The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual. Springer; 7th Edition edition (November 28, 2011)
Bott MJ, Patel AP, Crabtree TD, Morgenstern D, Robinson CG, Colditz GA, Wagar S, Kreisel D, Krupnicka AS, Patterson GA, Broderick S, Meyers BF, Puri V (2015) Role for surgical resection in the multidisciplinary treatment of stage IIIB non-small cell lung cancer. Ann Thorac Surg 99(6):1921–1928
Burdett SS, Stewart LA, Rydzewska L (2007) Chemotherapy and surgery versus surgery alone in non-small cell lung cancer. Cochrane Database Syst Rev 18(3):CD006157
Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal SA, Gore E, Machtay M, Sause W, Cox JD (2011) Sequential vs concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Nat Cancer Inst 103(19):1452–1460
Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94(446):496–509
Howlader N, Noone A, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse S, Kosary C, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner M, Lewis D, Chen H, Feuer E, Cronin K, Edwards B. SEER cancer statistics review. National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83(5):584–594
Reardon ES, Schrump DS (2014) Extended resections of non-small cell lung cancers invading the aorta, pulmonary artery, left atrium, or esophagus: can they be justified? Thorac Surg Clin 24(4):457–464
Sause WT, Scott C, Tayor S, Johnson D, Livingston R, Komaki R, Emami B, Curran WJ, Byhardt RW, Turrusu AT et al (1995) Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Nat Cancer Inst 87(3):198–205
Thomas M, Rube C, Hoffknecht P, Macha HN, Freitag L, Linger A, Willuch N, Hamm M, Sybrecht GW, Ukena D, Deppermann KM, Droge C, Risenbeck D, Heinecke A, Sauerland C, Junker K, Berdel WE, Semik M, German Lung Cancer Cooperative Group (2008) Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol 9(7):636–648
Suntharalingam M, Paulus R, Edelman MJ et al (2012) Radiation therapy oncology group protocol 02-20: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 84(2):456–463
Acknowledgments
Dr. Paul Christos was partially supported by the following grant: Clinical and Translational Science Center at Weill Cornell Medical College (UL1-TR000457-06).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
None.
Rights and permissions
About this article
Cite this article
Herskovic, A., Chitti, B., Christos, P. et al. Addition of Surgery After Radiation Significantly Improves Survival in Stage IIIB Non-small Cell Lung Cancer: A Population-Based Analysis. World J Surg 41, 758–762 (2017). https://doi.org/10.1007/s00268-016-3764-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00268-016-3764-y